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Abstract
Septic shock is a medical emergency that is associated with
mortality rates of 40-70%. Prompt recognition and institution of
effective therapy is required for optimal outcome. When the shock
state persists after adequate fluid resuscitation, vasopressor
therapy is required to improve and maintain adequate tissue/organ
perfusion in an attempt to improve survival and prevent the
development of multiple organ dysfunction and failure. Controversy
surrounding the optimum choice of vasopressor strategy to utilize
in the management of patients with septic shock continues. A
recent randomized study of epinephrine compared to nor-
epinephrine (plus dobutamine when indicated) leads to more
questions than answers.
The significant economic and mortality impact of severe
sepsis and septic shock has often resulted in some
controversy concerning optimum management strategies,
particularly in regard to choice of vasopressor support [1,2].
Annane and colleagues have recently reported on the
evaluation of two vasopressor strategies in a multicenter trial
of adult French septic shock patients [1]. The results of such
controlled clinical trials are valuable to clinicians since septic
shock has a reported mortality rate of 40-70% and currently
there are no convincing data supporting the use of one
vasopressor strategy over another [2]. Current consensus
recommendations from 11 different societies in the Surviving
Sepsis Campaign guidelines recommend either dopamine or
norepinephrine as the initial vasopressor for patients with
septic shock [3]. The 2004 practice parameter for
hemodynamic support of sepsis in adult patients from the
Society of Critical Care Medicine (SCCM) also recommends
the use of dopamine or norepinephrine as the initial
vasopressor(s) to use in adults with septic shock [4].
Dopamine was the traditional vasopressor choice for shock
management, until recent reports of dopamine resistance
and/or its potential for tachyarrhythmias resulted in nor-
epinephrine’s emergence as the preferred initial vasopressor
in North America and Europe [4-6].
In an attempt to determine the optimum vasopressor to use in
the management of patients with septic shock, Annane and
coworkers conducted a multicenter, prospective, randomized,
double-blind, controlled clinical trial evaluating epinephrine
versus norepinephrine (with dobutamine, if indicated) in the
management of a well-defined adult population with septic
shock [1]. The trial involved patients from 19 intensive care
units throughout France and was funded by the French
Ministry of Health. The study enrolled adults with well-defined
septic shock and evidence of organ dysfunction and/or
hypoperfusion. The primary outcome parameter was 28 day
all-cause mortality. Despite finding a significantly higher
arterial lactate level and lower pH during the first four days of
therapy in the epinephrine treated patients, there was not a
significant difference in 28 day all-cause mortality or other
important outcome parameters. Specifically, there was no
significant difference in discharge from the intensive care unit
(ICU) or hospital, hemodynamic parameters, vasopressor
withdrawal or organ dysfunction between the two treatment
strategies. Importantly, there was also no difference in
adverse events, such as arrhythmias or cardiac, neurologic, or
ischemic events [1].
As we consider these intriguing results from the study by
Annane and coworkers we are impressed by the intricacies of
study design and acknowledge their use of an expanded
definition for early septic shock in the inclusion and exclusion
criteria for study enrollment. The study was multi-centered,
randomized, with a double-blind treatment algorithm. The
study participants were reasonably well randomized at the
start. The majority of infections were community acquired with
the lung as the predominant site of infection. Given the
predominance of dopamine use in North America and
Europe, we were surprised investigators chose to compare
epinephrine and norepinephrine [4-6]. A trial design
comparing norepinephrine to dopamine, epinephrine, and
possibly vasopressin or phenylephrine would have had more
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clinical relevance for physicians in North America and Europe
[4-6]. The use of epinephrine as an initial vasopressor for the
management of septic shock would represent a significant
paradigm shift for North America and a majority of Europe
[5,6].
In regard to the study results, it is remarkable that the 28 day
all-cause mortality rate was 40% in the epinephrine and 34%
in the norepinephrine patients [1]. This impressive mortality
rate is lower than typical reports of 40-70% for septic shock
patients and raises questions regarding the reason for the
improvement in 28 day all-cause mortality rate [2]. This
observation is even more curious in light of the increased
arterial lactate and lower pH in the epinephrine group over
the first few days of management. Even though there was
recovery of this metabolic derangement by the fourth study
day, there did not appear to be any adverse sequelae. The
finding that epinephrine can produce exaggerated aerobic
glycolysis within muscles, decrease splanchnic and hepatic
blood flow, and may increase oxygen consumption, despite
an increase in oxygen delivery to the tissues likely explains the
increased arterial lactate and reduced pH [4,7,8]. Lactate has
been an important surrogate marker for assessing tissue
hypoperfusion [9]. Its measurement and prognostic implica-
tions have resulted in its incorporation into sepsis bundles
which have been widely adopted to guide initial sepsis
management [10,11]. Rivers and colleagues also reported a
distinct correlation between lactate clearance and outcome in
septic shock [9,12]. Increased lactate formation and delayed
clearance of lactate have been associated with increased
mortality rates in septic shock patients [9]. However, these
results demonstrate a survival benefit irregardless of the early
increases in lactate formation and presumed decrease in
clearance. The explanation for the positive survival benefits
could be related to the potential impact of the high
prevalence of steroid use (approximately 80% of all patients)
in this study. This percent of patients managed with
corticosteroid replacement therapy is higher that the typical
sepsis trial and represents yet another controversial area of
sepsis management [5]. Finally, it is noteworthy that adverse
events reported during this trial were similar. The authors also
evaluated the patients for significant ischemic events
involving the cardiac, neurologic, or peripheral circulation and
again there were no significant differences between the two
groups, supporting the safety of epinephrine in this study
population.
We applaud the efforts of the French investigators to
determine if there is a preferred vasopressor to use in septic
shock. The current study was particularly well-done, but
unfortunately, did not answer the question and raised
additional questions for the practicing intensivists. The
excellent survival results of this current trial (approximately
60%) for both epinephrine and norepinephrine treated
patients raises the question of whether the excellent outcome
was reflective of the vasopressor strategy, increased
corticosteroid use, or another variable. The epinephrine
outcomes were even more impressive in light of the initial
increase in arterial lactate and decrease in pH observed in
these patients compared to the norepinephrine treatment. To
help answer these questions and determine if there is a “best
vasopressor” we need another large, multicenter, prospec-
tive, randomized, controlled trial to compare norepinephrine,
dopamine, and epinephrine. Until this data becomes
available, it appears that there is no clear “best vasopressor”
to use in the management of adults with septic shock.
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